The Clinical Research by Cloclysis of Huchangqingdu Decoction in Blocking HBV-related Enterogenous Endotoxemia
|School||Shandong University of Traditional Chinese Medicine|
|Course||Chinese medical science|
|Keywords||chronic hepatitis B virus liver disease intestinal endotoxiemia Huchangqingdu decoction|
Objective: By cloclysis of Huchangqingdu Decoction.to confirm its clinical effect inblocking HBV-related enterogenous endotoxemia,expecting to provide an effective neweffective method for clinical treatment of the disease.Methods: On the base of routine treatment,60patients were divided into twogroups:Trial group and control group.Routine treatment includes resting,diet,reducedglutathione,pHGF,prostaglandin Erdeng and oral Chinese medicine decoction according tosyndrome differentiation;The trial group is treated with Huchangqingdu Decoction bycolon infusion administration.Trial group is given1/10concentration HuchangqingduDecoction by colon infusion administration. The course is20days,Observe the changes ofindicators like plasma endotoxin,glutamic-pyruvic transaminase,aspartate amino-transferase,prothrombin time activity as well as TCM symptom scores before and aftertreatment.Results:1.the total effective rate of trial group was93.9%, and77.7%of the controlgroup,the difference was statistically significant (P<0.05).2.The clinical efficacy of the testgroup in removing intestinal endotoxemia was96.9%, and the control group85.2%,thedifference was statistically significant (P<0.05).3.Improvement of glutamic-pyruvictransaminase,aspartate amino-transferase, albumin,total bilirubin and prothrombin timeactivity of the experimental group is better than the control group,the difference wasstatistically significant (P<0.05).4.TCM symptom scores and TCM syndromes effects ofthe trial group is significiantly better than the control group,the difference was statisticallysignificant (P<0.05).Conclusion: Cloclysis of Huchangqingdu Decoction is effective in blockingHBV-related enterogenous endotoxemia,And thus reduce or eliminate secondary liverinjury caused by endotoxin and cytokines,achieving the goal of blocking the lesions progress, significant improvement in clinical symptoms,improving the clinical efficacy inpatients with chronic liver disease.